Curis, Inc. (CRIS) Given Consensus Recommendation of “Hold” by Analysts
Shares of Curis, Inc. (NASDAQ:CRIS) have been given a consensus rating of “Hold” by the six analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $6.50.
A number of research analysts recently issued reports on CRIS shares. Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Monday, July 17th. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, BidaskClub upgraded shares of Curis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 17th.
Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its position in Curis by 58.7% during the 1st quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 13,448 shares during the period. Prudential Financial Inc. acquired a new stake in Curis during the 1st quarter valued at approximately $105,000. Dynamic Technology Lab Private Ltd increased its position in Curis by 22.3% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 7,638 shares during the period. OxFORD Asset Management LLP acquired a new stake in Curis during the 2nd quarter valued at approximately $115,000. Finally, Voya Investment Management LLC increased its position in Curis by 21.8% during the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 12,207 shares during the period. 44.72% of the stock is owned by institutional investors and hedge funds.
Shares of Curis (NASDAQ:CRIS) opened at 1.49 on Friday. The stock’s 50 day moving average is $1.81 and its 200 day moving average is $2.12. Curis has a 12 month low of $1.47 and a 12 month high of $3.72. The firm’s market cap is $214.38 million.
Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The business had revenue of $2.10 million during the quarter, compared to the consensus estimate of $2.08 million. Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The firm’s quarterly revenue was up 23.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.09) EPS. Analysts forecast that Curis will post ($0.40) EPS for the current fiscal year.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.